Sutro Biopharma (STRO) EBITDA Margin (2017 - 2025)
Sutro Biopharma (STRO) reported EBITDA Margin of 576.5% for Q4 2025, down 13584.0% on a YoY basis from N/an in Q4 2024, and down 15.31% sequentially from 499.94% in Q3 2025.
Sutro Biopharma (STRO) EBITDA Margin (2017 - 2025) Analysis & Trends
Sutro Biopharma (STRO) has 9 years of EBITDA Margin data on file, last reported at 576.5% in Q4 2025.
- For the quarter ending Q4 2025, EBITDA Margin fell 13584.0% year-over-year to 576.5%; the trailing twelve-month figure through Dec 2025 stood at 162.53% (up 22180.0% YoY), and the FY2025 full-year result was 154.53%, up 22981.0% from the prior year.
- EBITDA Margin slipped to 576.5% in Q4 2025, from 499.94% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 37.95% in Q4 2023 to a low of 797.17% in Q3 2024.
- A 5-year average of 331.22% and a median of 363.52% in 2023 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin jumped 60817 bps in 2023 and plunged 53710 bps in 2024, its largest moves.
- Tracing STRO's EBITDA Margin over 5 years: stood at 328.85% in 2021, then tumbled by 73 bps to 570.23% in 2022, then jumped by 107 bps to 37.95% in 2023, then plunged by 1261 bps to 440.66% in 2024, then sank by 31 bps to 576.5% in 2025.
- Business Quant data shows STRO's EBITDA Margin at 576.5% in Q4 2025, 499.94% in Q3 2025, and 5.25% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Sutro Biopharma | 202.59 Mn | 61.16 Mn | - | -576.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -576.50% |
| Sep 30, 2025 | -499.94% |
| Jun 30, 2025 | -5.25% |
| Mar 31, 2025 | -393.78% |
| Dec 31, 2024 | -440.66% |
| Sep 30, 2024 | -797.17% |
| Jun 30, 2024 | -189.39% |
| Mar 31, 2024 | -435.05% |
| Dec 31, 2023 | 37.95% |
| Sep 30, 2023 | -260.07% |
| Jun 30, 2023 | -443.52% |
| Mar 31, 2023 | -333.26% |
| Dec 31, 2022 | -570.23% |
| Sep 30, 2022 | -84.34% |
| Jun 30, 2022 | -68.97% |
| Mar 31, 2022 | -663.59% |
| Dec 31, 2021 | -328.85% |
| Sep 30, 2021 | -407.12% |
| Jun 30, 2021 | -34.96% |
| Mar 31, 2021 | -129.67% |